Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
Open Access
- 1 July 2019
- journal article
- research article
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 18 (03) , 232-237
Abstract
The aim of this study was to evaluate if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher detection rate compared to standard contrast CT imaging for patients with a rising prostate-specific antigen (PSA) following definitive treatment (i.e., curative radical prostatectomy, radiotherapy, and brachytherapy) for prostate cancer in a private hospital setting. A retrospective single-site clinical audit was conducted on 150 PSMA PET/CT scans done for patients with a rising PSA after definitive treatment for prostate cancer. All studies were performed using I and T Ga-68 PSMA produced on a Scintomics radiopharmaceutical unit (Munich). All scans were performed on a GE 710 PET/CT scanner. All studies were compared to standard CT and other imaging. Of the 150 patients who had a 68Gallium (Ga)-PSMA PET/CT for a rise in their PSA levels, 102/150 (68%) of patients had PSMA-avid scans compared to the conventional imaging group which had an overall detection rate of 42% (63/150). The rates of detection were 100%, 90%, 92%, 67%, and 25% at PSA levels of >10 μg/L, 5–10 μg/L, >1.5 μg/L, 0.5–1.5 μg/L, and 68Ga-PSMA PET/CT demonstrated a superior detection rate (P < 0.05) compared to conventional imaging, including patients with low PSA levels (<0.5 μg/L).Keywords
This publication has 30 references indexed in Scilit:
- Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathologyTheranostics, 2017
- Clinical impact of 68 Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approachBJU International, 2016
- Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate CancerEuropean Urology, 2016
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Significance and management of positive surgical margins at the time of radical prostatectomyIndian Journal of Urology, 2014
- Prostate Cancer: Value of Multiparametric MR Imaging at 3 T for Detection—Histopathologifc CorrelationRadiology, 2010
- CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTSJournal of Urology, 2004
- Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cellsThe Prostate, 2000
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999